Crestor and Benzodiazepines Interaction: What Patients and Clinicians Need to Know

Does a Pharmacokinetic Interaction Exist Between Rosuvastatin and Benzodiazepines?

No clinically relevant pharmacokinetic interaction exists between rosuvastatin and benzodiazepines. The two drug classes are metabolized through separate enzymatic pathways, and neither drug meaningfully inhibits or induces the enzymes responsible for the other's clearance. Standard DDI screening tools, including Lexicomp and Micromedex, assign this combination a "no known interaction" or "minor" classification.

Rosuvastatin's Metabolic Profile

Rosuvastatin undergoes limited hepatic metabolism. The FDA prescribing information for Crestor notes that approximately 90% of an absorbed dose is excreted unchanged, with only minor N-desmethyl metabolite formation via CYP2C9 [1]. CYP3A4 plays virtually no role in rosuvastatin clearance, which is the central reason why this statin has far fewer drug interactions than atorvastatin or simvastatin.

Hepatic uptake depends on the organic anion transporting polypeptides OATP1B1 and OATP1B3, and efflux depends on BCRP (breast cancer resistance protein). Drugs that inhibit these transporters, including cyclosporine, lopinavir/ritonavir, and elbasvir/grazoprevir, can raise rosuvastatin AUC by 2- to 7-fold and are the most clinically important interactions for this statin [1].

How Benzodiazepines Are Cleared

Most benzodiazepines rely on CYP3A4 or CYP2C19 for oxidative metabolism. Diazepam is metabolized by CYP2C19 and CYP3A4 to active metabolites including desmethyldiazepam [2]. Alprazolam and triazolam are nearly exclusively CYP3A4-dependent [3]. Lorazepam, oxazepam, and temazepam bypass phase-I oxidation entirely, undergoing direct glucuronidation, making them the lowest-interaction benzodiazepines regardless of co-medications [4].

Because rosuvastatin neither inhibits nor induces CYP3A4 or CYP2C19, it does not alter plasma concentrations of any benzodiazepine. Likewise, no benzodiazepine meaningfully inhibits OATP1B1, OATP1B3, or BCRP, so benzodiazepine use does not raise rosuvastatin exposure.

Pharmacodynamic Considerations: CNS Effects and Fall Risk

Pharmacodynamic overlap is where clinicians should focus attention. Rosuvastatin itself does not cause central nervous system (CNS) depression, but a small subset of statin users report cognitive symptoms including memory difficulties and confusion. The FDA added a class label update in 2012 noting postmarketing reports of "ill-defined memory loss or impairment" and "confusion" with all statins [5].

CNS Depression From Benzodiazepines

Benzodiazepines produce sedation, psychomotor impairment, and anterograde amnesia through positive allosteric modulation of GABA-A receptors [6]. These effects are dose-dependent and are amplified by age, renal impairment, and concurrent CNS-active medications.

The 2019 American Geriatrics Society Beers Criteria explicitly recommends avoiding benzodiazepines in adults 65 years and older because of an increased risk of cognitive impairment, delirium, falls, and fractures [7]. Patients on long-term benzodiazepines who are also initiating statin therapy are often older adults with established cardiovascular risk, making fall-risk counseling especially relevant.

Statin-Associated Cognitive Reports

Post-approval surveillance data submitted to FDA MedWatch through 2012 included reports of reversible memory impairment in statin users [5]. These reports do not establish causality, and the 2013 ACC/AHA Cardiovascular Risk Guideline Panel concluded that available evidence did not support a causal link between statins and dementia or persistent cognitive impairment [8]. Still, any patient who reports new cognitive symptoms while on both rosuvastatin and a benzodiazepine warrants re-evaluation of the benzodiazepine dose before attributing symptoms to the statin.

Myopathy and Neuromuscular Safety

Rosuvastatin carries a dose-dependent myopathy risk. The FDA label states that myopathy, defined as muscle aching or weakness with creatine kinase (CK) greater than 10 times the upper limit of normal, occurred in fewer than 0.1% of patients in controlled clinical trials [1]. Benzodiazepine-induced muscle relaxation could theoretically obscure early myopathy symptoms by blunting pain perception, although no published trial has quantified this masking effect.

Clinicians should instruct patients to report unexplained muscle pain, tenderness, or weakness regardless of benzodiazepine use. CK measurement at baseline and in response to symptoms remains the standard monitoring approach per the 2018 ACC/AHA Cholesterol Guideline [8].

Rosuvastatin Efficacy Evidence: Why the Statin Is Prescribed

Understanding why rosuvastatin is selected helps contextualize what is at stake if the combination is avoided unnecessarily.

JUPITER Trial Data

The JUPITER trial (N=17,802) evaluated rosuvastatin 20 mg versus placebo in patients with LDL <130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP ≥2.0 mg/L). After a median follow-up of 1.9 years, rosuvastatin reduced the primary composite cardiovascular endpoint by 44% (HR 0.56, 95% CI 0.46 to 0.69, P<0.00001) [9]. The trial was stopped early by the Data and Safety Monitoring Board because of the magnitude of benefit. This landmark result established rosuvastatin as a high-intensity statin with benefit extending beyond LDL reduction alone.

METEOR Trial: Subclinical Atherosclerosis

The METEOR trial (N=984) tested rosuvastatin 40 mg against placebo in patients with subclinical atherosclerosis and no prior cardiovascular events over 2 years. Rosuvastatin reduced the rate of progression of maximum carotid intima-media thickness (CIMT) by 0.0014 mm/year compared to placebo progression of +0.0131 mm/year (P<0.0001) [10]. No benzodiazepine-related adverse signals were noted in this cohort, and no pharmacokinetic substudy identified benzodiazepine use as a confounder.

Guideline-Recommended Intensity

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol classifies rosuvastatin 20 to 40 mg as a high-intensity statin expected to lower LDL-C by approximately 50% or more [8]. The guideline states: "High-intensity statin therapy should be initiated or continued as first-line therapy in patients 75 years or younger with clinical ASCVD." Benzodiazepine co-prescription is not listed as a contraindication or a reason to use a lower-intensity statin.

Drug Interactions That Actually Matter for Rosuvastatin

Given that benzodiazepines are not a true interaction concern, clinicians should direct attention to the interactions that do carry documented risk.

Transporter-Based Interactions

Cyclosporine increases rosuvastatin AUC by approximately 7-fold by inhibiting OATP1B1 and BCRP [1]. The FDA label caps the rosuvastatin dose at 5 mg daily in patients receiving cyclosporine. Lopinavir/ritonavir raises rosuvastatin AUC by approximately 2-fold, with a recommended dose ceiling of 10 mg daily [1].

Elbasvir/grazoprevir (for hepatitis C) increases rosuvastatin AUC by approximately 2.3-fold [1]. Gemfibrozil, often combined with statins for mixed dyslipidemia, inhibits OATP1B1 and raises rosuvastatin exposure; the combination is listed as contraindicated in the Crestor label [1].

Antacid Combinations

Simultaneous administration of an aluminum and magnesium hydroxide antacid reduces rosuvastatin Cmax by approximately 54% and AUC by approximately 47% [1]. Separating administration by at least 2 hours preserves bioavailability.

Warfarin

Rosuvastatin potentiates the anticoagulant effect of warfarin [1]. Patients initiating rosuvastatin while on warfarin require more frequent INR monitoring until stable. This interaction is listed as "moderate" in the FDA label and is clinically more significant than any theoretical concern with benzodiazepines.

Practical Decision Framework: Co-Prescribing Rosuvastatin With a Benzodiazepine

The following approach reflects the evidence hierarchy above and is designed for the prescribing clinician evaluating a patient who requires both agents.

Step 1. Confirm No Contraindicated Statin Interactions Are Present

Before worrying about benzodiazepines, screen the full medication list for cyclosporine, lopinavir/ritonavir, elbasvir/grazoprevir, and gemfibrozil. These are the interactions that require dose capping or avoidance.

Step 2. Select the Benzodiazepine With the Lowest Interaction Burden

If clinical need exists for a benzodiazepine in a patient on rosuvastatin, lorazepam, oxazepam, or temazepam carry lower overall DDI risk across the entire formulary because they bypass CYP oxidation entirely [4]. This choice matters most for patients on multiple medications, not because of the statin specifically.

Step 3. Assess Fall Risk Before Starting Both Agents

Complete a falls-risk assessment using the STEADI (Stopping Elderly Accidents, Deaths, and Injuries) algorithm, available from the CDC [11]. Any patient aged 65 years or older, or with a prior fall history, warrants focused counseling. The American Geriatrics Society notes that benzodiazepine use doubles the odds ratio for falls in older adults [7].

Step 4. Counsel on Myopathy Symptoms Independently of Benzodiazepine Use

Instruct patients to report muscle pain, tenderness, or weakness promptly. Obtain a baseline CK in patients at elevated myopathy risk, including those with renal impairment (eGFR <30 mL/min/1.73 m²), hypothyroidism, or personal or family history of muscular disease, per the 2018 ACC/AHA guideline [8].

Step 5. Schedule a 6-Week Follow-Up

Check a fasting lipid panel at 4 to 12 weeks after statin initiation to confirm LDL-C response. At this visit, review any new cognitive or neuromuscular symptoms. If the patient reports cognitive changes, assess benzodiazepine dose as the more likely contributor before attributing symptoms to rosuvastatin.

Special Populations

Older Adults (65 Years and Older)

The intersection of cardiovascular risk and benzodiazepine use is common in this group. A 2021 analysis published in the Journal of the American Geriatrics Society found that approximately 8.4% of Medicare beneficiaries aged 65 and older filled a benzodiazepine prescription in 2019 [12]. Many of these patients are also statin candidates under ACC/AHA guidelines. The absence of a pharmacokinetic interaction between rosuvastatin and benzodiazepines is reassuring, but pharmacodynamic caution about sedation and falls applies fully to this population.

Patients With Renal Impairment

Rosuvastatin exposure increases in renal disease. The FDA label recommends a starting dose of 5 mg daily for patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) not on hemodialysis, with a dose ceiling of 10 mg daily [1]. Benzodiazepines that rely on renal excretion of active metabolites, including diazepam's desmethyldiazepam, may also accumulate. In patients with renal impairment on both drugs, lorazepam's lack of active metabolites makes it a preferable choice [4].

Patients With Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease or unexplained persistent transaminase elevations [1]. Hepatic impairment also reduces benzodiazepine clearance. The combination warrants avoidance of both agents in the setting of decompensated liver disease.

Pregnant Patients

Rosuvastatin is contraindicated in pregnancy (FDA Pregnancy Category X) due to potential fetal harm [1]. Benzodiazepines are associated with neonatal withdrawal syndrome and possible teratogenicity [6]. Co-prescribing these agents in a patient of childbearing potential requires explicit contraception counseling.

Patient Counseling Points

Patients asking whether they can take Crestor with a benzodiazepine deserve a direct, accurate answer backed by the evidence above.

Key points to communicate:

• Rosuvastatin and benzodiazepines do not interact through liver enzymes in a way that changes either drug's blood levels.
• Both drugs can be taken as prescribed without adjusting doses for the combination itself.
• Benzodiazepines cause sedation and slow reflexes. Patients should avoid driving or operating machinery until they know how the benzodiazepine affects them, regardless of statin use.
• Report muscle pain, weakness, or unexplained fatigue to the prescriber promptly. These symptoms are unrelated to the benzodiazepine but need evaluation on their own merits.
• Do not stop rosuvastatin without medical guidance. Discontinuing a high-intensity statin abruptly can increase short-term cardiovascular risk, as demonstrated by observational data showing a rebound inflammatory effect within 30 days of cessation [13].

Monitoring Summary

| Parameter | Frequency | Trigger for Action | |---|---|---| | Fasting lipid panel | Baseline, then 4 to 12 weeks post-initiation, then annually | LDL-C reduction <30% suggests non-adherence or need for dose change | | Creatine kinase (CK) | Baseline in high-risk patients; symptom-driven otherwise | CK >10x ULN with symptoms = hold rosuvastatin | | Liver function tests | Baseline; repeat only if symptomatic | ALT or AST >3x ULN = evaluate and potentially discontinue | | Sedation and fall assessment | Each clinical encounter in patients ≥65 years | Any fall = reassess benzodiazepine appropriateness | | INR (if on warfarin) | More frequent monitoring at rosuvastatin initiation | INR changes require warfarin dose adjustment |